Teva, Active Biotech cut laquinimod doses on CV signal

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said they halted testing higher doses of laquinimod ( SAIK-MS) in two ongoing multiple sclerosis trials due to an imbalance in the number of non-fatal cardiovascular events. Active Biotech slid SEK4.05 (29%) to SEK9.75 on Monday.

The DMC for the Phase III CONCERTO and Phase II ARPEGGIO trials recommended the discontinuation. Teva spokesperson Nancy Leone said the majority of the CV events were myocardial ischemic events. ...